CN104414975A - Transdermal spray preparation for plastic mist membranization and preparation method of transdermal spray preparation - Google Patents
Transdermal spray preparation for plastic mist membranization and preparation method of transdermal spray preparation Download PDFInfo
- Publication number
- CN104414975A CN104414975A CN201310413369.0A CN201310413369A CN104414975A CN 104414975 A CN104414975 A CN 104414975A CN 201310413369 A CN201310413369 A CN 201310413369A CN 104414975 A CN104414975 A CN 104414975A
- Authority
- CN
- China
- Prior art keywords
- membranization
- transdermal
- mist
- plasticity
- transdermal spray
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention discloses a transdermal spray preparation for plastic mist membranization and a preparation method of the transdermal spray preparation. The transdermal spray preparation for plastic mist membranization comprises the following components in percentage by mass: 2%-20% of medicine, 2%-20% of mesoporous nano silica aerogel, 2%-30% of a dispersing agent, 1%-15% of atomizing agent, 1%-15% of a film-forming agent and 35-90% of a volatile solvent. The mesoporous nano silica aerogel is a controlled-release mesoporous nanometer carrier; the porosity of the mesoporous nano silica aerogel is 90%-99.8%; the aperture of the mesoporous nano silica aerogel is 20-100nm; the three-dimensional nano particle size is 2-70nm; the specific surface area is 100-1,000m<2>/g; the density is 0.003-30g/cm<3>; and the heat-conducting coefficient is 0.01-0.018w/m.k. According to the transdermal spray preparation, long-time continuous transdermal penetration of the medicine can be effectively achieved; the constant blood concentration is maintained; and the preparation has the characteristics of high transdermal absorption rate, high transdermal absorption amount and is stable and efficient.
Description
Technical field
The present invention relates to a kind of with meso-porous nano silicon dioxide plasticity mist membranization transdermal spray agent that is carrier and preparation method thereof.
Background technology
At present, by the conventional preparation containing medicine of interaction in vitro in human body, there is many defects in mainly patch, gel, emulsifiable paste, as the skin irritation that the closure function of patch to skin causes; Drug quality problems caused by the crystallization of medicine in patch; And after the administration of large area patch product, affect attractive in appearance etc.Semisolid dosage form is as gel and ointment, and its topmost problem is can not dosed administration exactly, easily removes because of friction, not only affects transdermal effect, and pollution clothes, reduce patient's compliance.
Ketoprofen, ibuprofen etc. are conventional NSAID (non-steroidal anti-inflammatory drug) (NSAIDs).Ketoprofen has a chiral centre, and generally all supply Clinical practice with the form of racemic modification, but only have d-isomer just to have antiinflammatory rheumatism and analgesic activity, levo form does not almost have pharmacologically active.The exploitation of developed country to single enantiomer is very paid attention to, and most of drugmaker starts to consider to set up chiral drug branch in their drug development portion.FDA has early just issued the guideline about chiral drug for 1992, and new drug research is from now on by the future development day by day towards single enantiomer.The use of dexketoprofen be conducive to reducing medicine toxicity and and nonactive enantiomer between influence each other, because his activity is 2 times of racemic modification, so the dosage of racemic modification half can be used for Clinical practice, the burden of liver and the formation of whole metabolite can be alleviated like this.Potential acylation reaction is had in addition between the acyl glucose aldehydic acid metabolite of ketoprofen and protein; easily bring out the selective toxicity of Immune Sensibility and tissue; and d-isomer is because eliminating the acyl glucose aldehydic acid of levo form thus reducing the quantity of this active metabolite, this is particularly useful to the patient that those hepatic and renal functions are bad.
Dexketoprofen is developed by Italian Menarini company, goes on the market first in 1996 in Spain.So far, oral formulations and the injection of dexketoprofen is had.
Studying data at home and abroad shows, the inhibitory action of ketoprofen to COX-1 has the selectivity of height.Experiment in vitro shows, stronger to the inhibitory action of COX-2, its IC50 is 0.024 μm of ol/L, by contrast, when very high concentration, (>1 μm of ol/L could produce the inhibitory action of 40% to levo form, thinks that the d-isomer containing trace with it is relevant.Observe the inhibitory action to intact cell COX-2, finding that the suppression IC50 of d-isomer to mononuclear cell COX-2 is 2 ~ 25 μm of ol/L, is 100 ~ 500 times of levo form.Therefore can infer, the inhibitory action of NSAIDs to COX-1 and COX-2 of chirality has certain selectivity, and former viewed racemic modification is produced by d-isomer COX-2 inhibitory action.
The modal untoward reaction of NSAIDs is gastrointestinal toxicity, especially with old people and long-term prescription person the most common.The most serious untoward reaction is gastrointestinal hemorrhage, also has protein minimizing, bile malabsorption etc. in addition.Toxicity research shows, rat single oral dose 10 ~ 20mg/kg d-isomer does not affect intestinal mucosa, and the racemic modification of 20 ~ 40mg/kg has obvious infringement to small intestinal and cecum mucosa, this toxicity may be that the synergism between levo form and d-isomer causes.Pharmacokinetic shows, health volunteer's single takes 12.5mg or 25mg, can at 0.25-0.75 hour blood drug level peaking, and peak concentration is respectively 1.4mg/L and 3.1mg/L.Dexketoprofen mainly exists with the form of prototype medicine, hydroxylation metabolism thing and corresponding glucosiduronate metabolite.The drug main of about 70-80% will want excretion from urine in latter 12 hours with glucuronide conjugate form at clothes.
Rheumatoid arthritis is frequently-occurring disease, the commonly encountered diseases of serious threat human health, and be the autoimmune disease that is main manifestations with multi-joint chronic inflammatory disease, disability rate is higher.Pain is one of modal symptom of malignant tumor patient.According to World Health Organization's statistics, the annual new cancer patient 7,000,000 in the whole world, wherein 30%-50% is with pain in various degree, has a strong impact on the daily life of patient.Implement the misery that tumor analgesia therapy can alleviate cancer patient.Experiment proves, KPF is a kind of alleviation and the active drug for the treatment of of cancer pain, and the analgesic effect of oral KPF quite or be better than morphine.Dexketoprofen has analgesia and antipyretic properties concurrently, be mainly used in clinically treating ankylosing spondylitis, rheumatoid arthritis and osteoarthritis, abroad also for postoperative analgesia, dentistry pain, acute visceral pain, acute muscle injury, chronic cancer pain and primary dysmenorrhea etc.
Summary of the invention
The object of this invention is to provide transdermal spray agent of a kind of plasticity mist membranization and preparation method thereof, to improve the compliance of patient medication.
The transdermal spray agent of described plasticity mist membranization, is made up of the component of following parts by weight percentage ratio:
Preferably
Described meso-porous nano aerosil is controlled release meso-porous nano carrier, porosity 90%-99.8%; Aperture is 20 ~ 100nm; Three-dimensional manometer particle diameter is 2 ~ 70nm; Specific surface area 100-1000m
2/ g; Density 0.003g-30g/cm
3; Heat conductivity 0.01-0.018w/mk.
Described meso-porous nano aerosil, the aerosil of the hydrophobicity that Germany and Britain's dust Lik-Sang Asia-Pacific Electronics Co., Ltd. can be adopted to produce, hydrophilic or both sexes; Density 12.5-18kg/m
3, specific surface area 500-650m
2/ g, porosity 95-98%, aperture 10-70nm, pore volume 3.5ml/g, heat conductivity 0.01-0.018w/mk.
Described dispersant comprises isopropyl alcohol, ethanol, propylene glycol, glycerol, n-octyl alcohol or n-dodecanol; Preferred propylene glycol;
Described propellant is selected from sulfoxide type, pyrrolones, terpenes, amine, phosphide class, laurocapram, surfactant, sodium laurylsulfate, fatty acid or fatty acid ester;
Described sulfoxide type is selected from dimethyl sulfoxide or Kui methyl sulfoxide;
Described pyrrolones comprises 2-pyrrolidone, 5-methyl-2-pyrrolidone, 1,5-dimethyl-2-pyrrolidone, N-methyl pyrrole iron alkane ketone;
Described terpenes comprises eucalyptole, limonene or orange blossom tree alcohol;
Described phosphide class comprises lecithin, fabaceous lecithin or phosphatidyl glycerol;
Described fatty acid comprises oleic acid or lauric acid;
Described fatty acid ester comprises LA, isopropyl myristate, propylene glycol dipelargonate or ethyl sebacate;
Most preferred, propellant possesses the ability of excellent dissolution medicine thoroughly, is selected from isopropyl myristate, azone or LA;
Described film former is alcohol insoluble hydrophilic macromolecule, comprises cellulose derivative as acrylic resin, hydroxypropyl cellulose, copolyvidone, low molecular weight polyvinyl pyrrolidone, preferably polyethylene ketopyrrolidine (PVP-K12, PVP-K15, PVP-K30).The good compatibility is had with the solvent in medicinal liquid and propellant.And after administration acts on skin, can have and well hold attached property, anti-washing property and good outward appearance.
Described volatile solvent, can be ethyl acetate, low molecule alcohols etc.
Most preferred, from security consideration, solvent flashing selects ethanol and propylene glycol;
Described medicine is dexketoprofen or ibuprofen;
The preparation method of the transdermal spray agent of described plasticity mist membranization, comprises the steps:
(1) membrane material is added in solvent flashing, and add propellant, form uniform solution system;
(2) medicine is added in dispersant, form uniform pastille dispersion;
(3) controlled release meso-porous nano carrier material is put into the dispersion (2) prepared, ultrasonic 20 ~ 40 minutes, make meso-porous nano carrier material active adsorption medicine, form the controlled release system of bag medicine carrying thing;
(4) controlled release system prepared by the solution system (1) prepared and (3) mixes, ultrasonic degas, can obtain the transdermal spray agent of described plasticity mist membranization.
Mechanism of action of the present invention is such:
Medicinal liquid acts on skin, and then solvent volatilization, forms drug-reservoir, then sustained release.
The transdermal spray agent of the plasticity mist membranization of invention, by dosing pump, acts on skin by the medicinal liquid of correct dose with form that is vaporific or liquid, after administration, form the plastic membrane of atomization at skin surface, in medicinal liquid, solvent evaporates rapidly, and medicine then forms " stealthy bank " at skin surface.Therefore, solution system is applied to transdermal administration can not produce zest to skin because of closure function, and, in conjunction with the use of dosing pump, the problem of dosed administration can also be solved.
In order to solve in spraying system application process, because solvent volatilization causes the quick crystallize of medicine, thus affect the Transdermal absorption of medicine, inventor finds, adopts mesoporous absorption and the Drug controlled release of aerosil, can increase drug loading simultaneously.
The architectural feature of described aerosil is cylindrical shape multi-branched nanoporous three network structures having high-permeability, and have high hole ratio, extremely low density, high-specific surface area, superelevation pore volume rate, its body density is at 0.003-0.500g/cm
3it is adjustable in scope that (density of air is 0.0129g/cm
3).The large specific surface area that mesopore silicon dioxide nano material has, higher porosity, regular orderly pore passage structure, homogeneous adjustable aperture and become the excellent carrier of medicine without advantages such as physiological-toxicity.Wherein there are MCM-41 and SBA-15 (Santa Barbava USA, SBA) two kinds of Metaporous silicon dioxide materials as pharmaceutical carrier most study most is representational.Generally speaking, the surface area that mesoporous silicon oxide utilizes it huge and strong absorbability, can be carried on its nano pore inner by drug molecule, and the release medicine slowly continued; For patent drug of the present invention, by the adjustment to mesoporous silicon oxide aperture and internal gutter topological structure, its nano pore or three dimensional structure can be relied on, medicine is present in inside, duct with molecule or amorphous absorption, thus effectively control the rate of release of medicine, increase drug loading, suppress crystallize.
Medicinal liquid skin show formed plastic membrane form with the prescription of atomized liquid, spray type and operating condition relevant.Solution relative density and viscosity play the part of less role in aerosol apparatus output, and because great majority are aqueous solvent, but when being atomized viscosity higher solution, viscosity is exactly an important factor.Research shows, for low viscosity liquid, the liquid size of generation is directly proportional to liquid viscosity, and the impact of relative density on droplet size is less.Viscosity is comparatively complicated on the impact of the size of drop.For the aerosol apparatus of given solution, operating pressure is the principal element determining aerosol apparatus output.Result of the test shows that the output of operating pressure and medicine has functional relationship.
When spraying system of the present invention uses, dosage is once a day, one time one spray, take area as 12-24cm2 is suitable.Dexketoprofen metered dose preparation provided by the invention, dispersant enables medicine be dispersed in uniformly in solvent system, and film former can help product closely to paste skin, and wherein propellant helps to open skin passage, the Transdermal absorption of significantly increasing medicament; Meso-porous nano carrier material active adsorption medicine, forms the controlled release system of bag medicine carrying thing, realizes the controllable release of medicine, and when after the volatilization of solvent flashing short time, drug level increases sharply, and the existence of meso-porous nano carrier material can suppress the crystallization of medicine.
The transdermal spray agent of plasticity mist provided by the invention membranization, can improve the compliance of patient medication.Animal experiment proves, the transdermal spray agent of plasticity mist of the present invention membranization, can continue drug release and the transdermal of 24 hours.To be released in human body by skin at this drug-supplying system Chinese medicine and to play drug effect, stable blood drug level can be maintained simultaneously, reduce and take frequency, increase compliance and the compliance of patient; Simultaneously transdermal route avoids the first pass effect of drug oral through gastrointestinal tract and liver, has higher bioavailability, medical applications has clear superiority.Effectively can realize the sustained transdermal of medicine long period, maintain constant blood drug level, and preparation percutaneous absorption rate is fast, Transdermal absorption amount is high, has stable, efficient feature.
Accompanying drawing explanation
Fig. 1 is the accumulation dermal penetration rate figure of medicine in 24 hours.
Detailed description of the invention
Prescription is in table 1, table 2 and table 3.Table 1 is disperse system, and table 2 is controlled release system, and table 3 is respectively: embodiment 1+7=embodiment 13, embodiment 2+8=embodiment 14, by that analogy.
Table 1, embodiment 1-6
Table 2, embodiment 7-12
Embodiment 13-18 is the mixture of table 1 and table 2 two solution systems.After mixing, ultrasonic degas, obtains the transdermal spray system of efficient plasticity mist membranization.Select different sprayer units.Prescription is composed as follows:
Table 3, embodiment 13-18
Adopt measurement of size of aerosol standard to detect embodiment 1-18 successively, the results are shown in Table 4:
Table 4, regulates atomized flow, in 4L/min, 8L/min, measures the aerocolloidal particle diameter of above-mentioned prescription with laser diffractometry
Result proves that the mass size median of embodiment 13-18 when the atomized flow of 4L/min, 8L/min meets this prescription be administered systemically.
In conjunction with metered dose agent, quality evaluation is carried out to embodiment 13-18:
Administration area after each administration is evaluated, and weighing area is 100cm
2the quality of the paper of (10 × 10cm) is 0.8952g.By preparing metered dose agent from same blank sheet of paper 5cm place, medicinal liquid is sprayed on paper.By the part of the occurrence of wetness on paper, profile sketched the contours tailing edge margin line with pen and cut this part and weigh.Repeat 6 times, then each following formulae discovery of administration active area:
Ax=0.8952×100/Wx
The results are shown in Table 5:
The mensuration (n=6) of table 5 metered dose agent administration active area
Embodiment 13-18 preparation prescription is put in 30 ° of inclinations, weighs after 3 days, compare with weighing results before when 30 ° of inclinations are not put 3 days.Unknown significance difference.
The homogeneity of every spray amount is investigated.Weigh after 0,1,5,10,20,40 time in metered dose agent.The weight of every spray amount is the number of times of weight divided by ejection of minimizing.Experimental result is as follows:
The above results shows, the invention provides with penetrating agent is the novel preparation capable of permeating skin of pharmaceutical carrier, can improve the compliance of patient medication.Effectively can realize the sustained transdermal of medicine long period, maintain constant blood drug level, and preparation percutaneous absorption rate is fast, Transdermal absorption amount is high, has stable, efficient feature.
The present invention and relative theory are equally applicable to the medicine of similar physicochemical properties, as ibuprofen etc.
According to " percutaneous dosing novel form ", (Zheng Jun democracy is compiled, People's Health Publisher publishes) in the method that provides, adopt Franz diffusion cell, choose the immediate isolated pig skin with application on human skin and carry out permeation test in vitro, measure the infiltration rate of preparation at isolated pig skin of embodiment 13 ~ 18, result is as table 4, and the accumulation dermal penetration rate of embodiment preparation in 24 hours is shown in Fig. 1.
The dermal penetration rate of the different embodiment Chinese medicine of table 6
Claims (8)
1. the transdermal spray agent of plasticity mist membranization, is characterized in that, is made up of the component of following parts by weight percentage ratio:
The percentage ratio sum of component is 100%;
Described meso-porous nano aerosil is controlled release meso-porous nano carrier, porosity 90%-99.8%; Aperture is 20 ~ 100nm; Three-dimensional manometer particle diameter is 2 ~ 70nm; Specific surface area 100-1000m
2/ g; Density 0.003g-30g/cm
3; Heat conductivity 0.01-0.018w/mk.
2. the transdermal spray agent of plasticity mist membranization, is characterized in that, is made up of the component of following parts by weight percentage ratio:
The percentage ratio sum of component is 100%;
Described meso-porous nano aerosil is controlled release meso-porous nano carrier, porosity 90%-99.8%; Aperture is 20 ~ 100nm; Three-dimensional manometer particle diameter is 2 ~ 70nm; Specific surface area 100-1000m
2/ g; Density 0.003g-30g/cm
3; Heat conductivity 0.01-0.018w/mk.
3. the transdermal spray agent of plasticity mist according to claim 1 membranization, is characterized in that, described meso-porous nano aerosil is the aerosil of hydrophobicity, hydrophilic or both sexes.
4. the transdermal spray agent of plasticity mist according to claim 3 membranization, is characterized in that, described meso-porous nano aerosil is the aerosil of hydrophobicity, hydrophilic or both sexes.
5. the transdermal spray agent of plasticity mist according to claim 1 membranization, is characterized in that, described dispersant comprises isopropyl alcohol, ethanol, propylene glycol, glycerol, n-octyl alcohol or n-dodecanol.
6. the transdermal spray agent of plasticity mist according to claim 1 membranization, it is characterized in that, described propellant is selected from sulfoxide type, pyrrolones, terpenes, amine, phosphide class, laurocapram, surfactant, sodium laurylsulfate, fatty acid or fatty acid ester;
Described sulfoxide type is selected from dimethyl sulfoxide or Kui methyl sulfoxide;
Described pyrrolones comprises 2-pyrrolidone, 5-methyl-2-pyrrolidone, 1,5-dimethyl-2-pyrrolidone, N-methyl pyrrole iron alkane ketone;
Described terpenes comprises eucalyptole, limonene or orange blossom tree alcohol;
Described phosphide class comprises lecithin, fabaceous lecithin or phosphatidyl glycerol;
Described fatty acid comprises oleic acid or lauric acid;
Described fatty acid ester comprises LA, isopropyl myristate, propylene glycol dipelargonate or ethyl sebacate;
Described film former is alcohol insoluble hydrophilic macromolecule, comprises cellulose derivative as acrylic resin, hydroxypropyl cellulose, copolyvidone, low molecular weight polyvinyl pyrrolidone;
Described volatile solvent, can be ethyl acetate or low molecule alcohols.
7. the transdermal spray agent of the plasticity mist membranization according to any one of claim 1 ~ 6, is characterized in that, described medicine is dexketoprofen or ibuprofen.
8. the preparation method of the transdermal spray agent of the plasticity mist membranization according to any one of claim 1 ~ 7, is characterized in that, comprise the steps:
(1) membrane material is added in solvent flashing, and add propellant, form uniform solution system;
(2) medicine is added in dispersant, form uniform pastille dispersion;
(3) controlled release meso-porous nano carrier material is put into the dispersion (2) prepared, ultrasonic 20 ~ 40 minutes, make meso-porous nano carrier material active adsorption medicine, form the controlled release system of bag medicine carrying thing;
(4) controlled release system prepared by the solution system (1) prepared and (3) mixes, ultrasonic degas, can obtain the transdermal spray agent of described plasticity mist membranization.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310413369.0A CN104414975B (en) | 2013-09-11 | 2013-09-11 | Transdermal spray agent of plasticity mist membranization and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310413369.0A CN104414975B (en) | 2013-09-11 | 2013-09-11 | Transdermal spray agent of plasticity mist membranization and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104414975A true CN104414975A (en) | 2015-03-18 |
| CN104414975B CN104414975B (en) | 2017-11-24 |
Family
ID=52965802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310413369.0A Active CN104414975B (en) | 2013-09-11 | 2013-09-11 | Transdermal spray agent of plasticity mist membranization and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104414975B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105906435A (en) * | 2016-04-27 | 2016-08-31 | 安徽乙地生态科技有限公司 | Fogging agent for spraying and preparation method thereof |
| CN109755113A (en) * | 2017-11-01 | 2019-05-14 | 天津环鑫科技发展有限公司 | A kind of One Diffusion Process technique adjusting diffusion atmosphere |
| CN109911907A (en) * | 2017-12-13 | 2019-06-21 | 天津龙华诚信粉体技术有限公司 | A kind of preparation method and product of ultra-fine high oil absorption value food grade silicon dioxide |
| CN111743976A (en) * | 2020-07-03 | 2020-10-09 | 广西医科大学 | Application of silicon dioxide aerogel in preparation of osteoarthritis treatment drug |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102018671A (en) * | 2011-01-05 | 2011-04-20 | 浙江大学 | Estradiol transdermal spray and preparation method thereof |
| US20110123601A1 (en) * | 2009-11-23 | 2011-05-26 | National Tsing Hua University | Biofunctionalized phospholipid-capped mesoporous silica nanoshuttles for targeted drug delivery |
| CN102199312A (en) * | 2011-03-07 | 2011-09-28 | 青岛大学 | Mesoporous silica particle compound carrier with controlled-release function as well as preparation method and application thereof |
-
2013
- 2013-09-11 CN CN201310413369.0A patent/CN104414975B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110123601A1 (en) * | 2009-11-23 | 2011-05-26 | National Tsing Hua University | Biofunctionalized phospholipid-capped mesoporous silica nanoshuttles for targeted drug delivery |
| CN102018671A (en) * | 2011-01-05 | 2011-04-20 | 浙江大学 | Estradiol transdermal spray and preparation method thereof |
| CN102199312A (en) * | 2011-03-07 | 2011-09-28 | 青岛大学 | Mesoporous silica particle compound carrier with controlled-release function as well as preparation method and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| 胡延臣等: "纳米多孔二氧化硅作为药物载体的研究进展", 《沈阳药科大学学报》 * |
| 陈蔚萍等: "硅气凝胶负载洛伐他丁的研究", 《河南大学学报(自然科学版)》 * |
| 高传傅: "介孔材料的合成及其作为药物载体的研究", 《中国博士学位论文全文数据库 工程科技Ⅰ辑》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105906435A (en) * | 2016-04-27 | 2016-08-31 | 安徽乙地生态科技有限公司 | Fogging agent for spraying and preparation method thereof |
| CN109755113A (en) * | 2017-11-01 | 2019-05-14 | 天津环鑫科技发展有限公司 | A kind of One Diffusion Process technique adjusting diffusion atmosphere |
| CN109911907A (en) * | 2017-12-13 | 2019-06-21 | 天津龙华诚信粉体技术有限公司 | A kind of preparation method and product of ultra-fine high oil absorption value food grade silicon dioxide |
| CN111743976A (en) * | 2020-07-03 | 2020-10-09 | 广西医科大学 | Application of silicon dioxide aerogel in preparation of osteoarthritis treatment drug |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104414975B (en) | 2017-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tekade | Basic fundamentals of drug delivery | |
| ES2326043T3 (en) | PERCUTANEOUS THERAPEUTIC SYSTEM FOR THE ADMINISTRATION OF LIPOFILOUS AND / OR LITTLE PERMEABLES ACTIVE SKIN PRINCIPLES. | |
| JP2003532668A (en) | Pharmaceutical composition for transdermal administration of anti-inflammatory agent | |
| CA2371912A1 (en) | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof | |
| CN104414975A (en) | Transdermal spray preparation for plastic mist membranization and preparation method of transdermal spray preparation | |
| CN106074453B (en) | Lappaconitine Gel emplastrum and preparation method thereof | |
| BR112015024271B1 (en) | TRANSDERMAL DELIVERY SYSTEM | |
| US9283190B2 (en) | Highly efficient and long-acting slow-release formulation of poorly soluble drugs and preparation method thereof | |
| CN107921033B (en) | Bioadhesive compositions of granisetron for intranasal administration | |
| CN105338970B (en) | Medicament capsule compound formulation comprising Tadalafei and Tamsulosin | |
| RU2018109496A (en) | PHARMACEUTICAL COMPOSITION CONTAINING ELECTROHYDRODYNAMIC PRODUCED FIBERS, COMPOSITION HAVING AN IMPROVED HOLD TIME IN THE PLACE OF APPLICATION | |
| JP2014055119A (en) | Drug-containing ultrafine fiber and utilization thereof | |
| Muñoz et al. | Design, development and characterization of transdermal patch of methadone | |
| Shi et al. | Electrospinning of artemisinin-loaded core-shell fibers for inhibiting drug re-crystallization | |
| USRE46397E1 (en) | Slow release of organic salts of local anesthetics for pain relief | |
| CN102940618A (en) | Loxoprofen organic amine salt transdermal patch and preparation method thereof | |
| CN103830206A (en) | Transdermal delivery preparation in three-dimensional netty spatial configuration of agomelatine and preparation method thereof | |
| Sweety et al. | Fabrication of stimuli gated nanoformulation for site-specific delivery of thymoquinone for colon cancer treatment–insight into thymoquinone’s improved physicochemical properties | |
| MY150820A (en) | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance | |
| Kharia et al. | Overview of Transdermal Medicated Patches with its research updates in preceding years | |
| JP2011046666A (en) | Medicinal composition | |
| CN112057436A (en) | Lipid-containing pharmaceutical preparation, transdermal drug delivery patch, and method for producing the same | |
| EP1613283A1 (en) | Composition, method and pharmaceutical preparation for pharmaceutical spray suspensions | |
| CN109875954A (en) | A kind of medical instruments composition and preparation method thereof | |
| CN102178661B (en) | Levo-tetrahydropalmatine transdermal drug delivery preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |